Moleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2023 Earnings Call Transcript November 13, 2023
Operator: Greetings, and welcome to the Moleculin Biotech Third Quarter 2023 Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded. At this time, I’d like to turn the call over to Jenene Thomas, Investor Relations. Thank you. You may begin.
Jenene Thomas: Thank you, Gerald. Good morning, and welcome everyone. At this time, I would like to remind our listeners that remarks made during this webcast may state management’s intentions, beliefs, expectations, or future projections. These are forward-looking statements and involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the safe harbor provisions of the federal securities laws and are based on Moleculin’s current expectations and actual results could differ materially. As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that could cause actual results to differ materially from these contemplated by such forward-looking statements are discussed in the periodic reports, Moleculin files with the Securities and Exchange Commission.
A scientist in a laboratory working on drug research.
These documents are available in the Investors section of the company’s website and on the Securities and Exchange Commission’s website. We encourage you to review these documents carefully. Additionally, certain information contained in this webcast relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company’s own estimates and research. While the company believes these third-party sources to be reliable as of the date of this presentation, it does not independently verify and makes no representation as to the adequacy, fairness, accuracy or completeness of or that any independent source of verified any information obtained from third party source. Any data discussed regarding clinical trials and progress are considered preliminary and subject to change.
So joining us on the call today from the Moleculin’s management team are Walter Klemp, Chairman and Chief Executive Officer; Dr. John Paul Waymack, Senior Chief Medical Officer; and Jonathan Foster, the Executive Vice President and Chief Financial Officer. I would now like to turn the call over to Walter Klemp, Chairman and CEO. Wally, please proceed.
Walter Klemp: Thanks, Jenene. Hello, everyone. I’m Wally Klemp, Founder, CEO, and Chairman of Moleculin Biotech. We are really excited to welcome you to this Q3 earnings call. We’ve been saying for some time now that this would be our year of data, and we are finally able to deliver on the Phase 2 data we’ve been hoping for. To be clear, this is preliminary and subject to change, and there’s a lot more data to come in the next few quarters. But we have a start, and it’s a good one. We’re going to share it with you on this call. As we walk through the data today, I’d ask you to keep in mind one of our core beliefs. That is that the most important therapeutic tool for both AML and advanced STS has been and continues to be an anthracycline.
See also Jim Simons Stock Portfolio: 12 Biggest Healthcare Stocks and 13 Cheap Energy Stocks To Buy.
To continue reading the Q&A session, please click here.